|
60 Companies |
|
66 Products |
|
66 Products |
|
77 Mechanisms of Action |
|
2 Trials |
|
576 News |
|
| «123456789101112» |
- Enrollment closed, Post-transplantation: Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (clinicaltrials.gov) - Oct 30, 2013
P2, N=42, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting
- | New P2 trial: Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome (clinicaltrials.gov) - Oct 21, 2013
P2, N=38, Recruiting, Sponsor: Ferring Pharmaceuticals
- | Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment change: MACS0911: Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response (clinicaltrials.gov) - Oct 17, 2013
P4, N=45, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=83 --> 45
- Enrollment change: Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure (clinicaltrials.gov) - Oct 15, 2013
P=N/A, N=71, Recruiting, Sponsor: National Eye Institute (NEI)
N=83 --> 45 N=53 --> 71
- Enrollment open: Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure (clinicaltrials.gov) - Oct 15, 2013
P=N/A, N=71, Recruiting, Sponsor: National Eye Institute (NEI)
N=53 --> 71 Completed --> Recruiting
- ||| basmisanil (RG1662) / Roche
Enrollment open: A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832) (clinicaltrials.gov) - Oct 6, 2013
P=N/A, N=170, Recruiting, Sponsor: Hoffmann-La Roche
Completed --> Recruiting Not yet recruiting --> Recruiting
- MK-2206 / Merck (MSD)
Trial completion: MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia (clinicaltrials.gov) - Sep 26, 2013
P1, N=45, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- lenalidomide / Generic mfg., azacitidine / Generic mfg.
Trial termination: Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes (clinicaltrials.gov) - Sep 25, 2013
P1, N=0, Terminated, Sponsor: Technische Universit
Active, not recruiting --> Completed Recruiting --> Terminated; The primary objective has already been answered with the number of recruited patients.
- lenalidomide / Generic mfg.
Trial termination: LENAMAINT: Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) (clinicaltrials.gov) - Sep 25, 2013
P2, N=10, Terminated, Sponsor: Technische Universit
Recruiting --> Terminated; The primary objective has already been answered with the number of recruited patients. Recruiting --> Terminated; Low recruitment, scientific rationale not applicable anymore to all patients and possible induction of GvHD by the study drug
- lenalidomide / Generic mfg.
Enrollment change: LENAMAINT: Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) (clinicaltrials.gov) - Sep 25, 2013
P2, N=10, Terminated, Sponsor: Technische Universit
Recruiting --> Terminated; Low recruitment, scientific rationale not applicable anymore to all patients and possible induction of GvHD by the study drug N=50 --> 10
- cytarabine / Generic mfg.
Enrollment change: Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder (clinicaltrials.gov) - Aug 21, 2013
P3, N=0, Withdrawn, Sponsor: Children's Oncology Group
N=50 --> 10 N=180 --> 0
- Enrollment change: Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia (clinicaltrials.gov) - Aug 20, 2013
P3, N=25, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
N=180 --> 0 N=280 --> 25
- || Enrollment change: Non-invasive Chromosomal Examination of Trisomy Study (clinicaltrials.gov) - Aug 14, 2013
P=N/A, N=18955, Active, not recruiting, Sponsor: Ariosa Diagnostics, Inc
N=280 --> 25 N=25000 --> 18955
- || Enrollment closed: Non-invasive Chromosomal Examination of Trisomy Study (clinicaltrials.gov) - Aug 14, 2013
P=N/A, N=18955, Active, not recruiting, Sponsor: Ariosa Diagnostics, Inc
N=25000 --> 18955 Recruiting --> Active, not recruiting
- Enrollment closed: Cognitive Remediation in 22q11DS (clinicaltrials.gov) - Aug 4, 2013
P=N/A, N=36, Active, not recruiting, Sponsor: Duke University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | arbaclofen (STX209) / Allos Pharma
Trial termination: An Open Label Extension Study in Subjects With Fragile X Syndrome (clinicaltrials.gov) - Jul 29, 2013
P3, N=357, Terminated, Sponsor: Seaside Therapeutics, Inc.
Recruiting --> Active, not recruiting Enrolling by invitation --> Terminated
- ||||||| arbaclofen (STX209) / Allos Pharma
Trial completion: Harbor-C: Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome (clinicaltrials.gov) - Jul 29, 2013
P3, N=172, Completed, Sponsor: Seaside Therapeutics, Inc.
Enrolling by invitation --> Terminated Active, not recruiting --> Completed
- ||||||| arbaclofen (STX209) / Allos Pharma
Trial completion: Harbor-A: Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome (clinicaltrials.gov) - Jul 29, 2013
P3, N=125, Completed, Sponsor: Seaside Therapeutics, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | arbaclofen (STX209) / Allos Pharma
Biomarker, Trial completion: Biomarker and DNA Collection in Subjects Participating in Protocol 22003 (clinicaltrials.gov) - Jul 29, 2013
P=N/A, N=32, Completed, Sponsor: Seaside Therapeutics, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- arbaclofen (STX209) / Allos Pharma
Biomarker, Trial completion: Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001 (clinicaltrials.gov) - Jul 29, 2013
P=N/A, N=0, Completed, Sponsor: Seaside Therapeutics, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Byetta (exenatide) / AstraZeneca
Enrollment closed: Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome (clinicaltrials.gov) - Jul 24, 2013
P=N/A, N=20, Active, not recruiting, Sponsor: Children's Hospital Los Angeles
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Orgalutran (ganirelix acetate) / Organon, Follistim AQ Cartridge (follitropin beta) / Organon
Preclinical, Trial termination, Heterogeneity: A Study of the Effects of a Novel Ovarian Stimulation Regimen on Embryo Aneuploidy Rates in In Vitro Fertilization (IVF) (clinicaltrials.gov) - Jul 18, 2013
P4, N=34, Terminated, Sponsor: Bart CJM Fauser
Recruiting --> Active, not recruiting Recruiting --> Terminated; Due to a very slow inclusion rate.
- Orgalutran (ganirelix acetate) / Organon, Follistim AQ Cartridge (follitropin beta) / Organon
Preclinical, Enrollment change, Heterogeneity: A Study of the Effects of a Novel Ovarian Stimulation Regimen on Embryo Aneuploidy Rates in In Vitro Fertilization (IVF) (clinicaltrials.gov) - Jul 18, 2013
P4, N=34, Terminated, Sponsor: Bart CJM Fauser
Recruiting --> Terminated; Due to a very slow inclusion rate. N=110 --> 34
- Enrollment open: Hypoglycemia in Prader-Willi Syndrome (clinicaltrials.gov) - Jul 14, 2013
P=N/A, N=20, Recruiting, Sponsor: University of Florida
N=110 --> 34 Not yet recruiting --> Recruiting
- ||| Trial completion: Comparison of Aneuploidy Risk Evaluations (clinicaltrials.gov) - Jul 11, 2013
P=N/A, N=3000, Completed, Sponsor: Verinata Health, Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| trofinetide (NNZ-2566) / Neuren, Acadia Pharma
New P2 trial: A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome (clinicaltrials.gov) - Jul 8, 2013
P2, N=60, Recruiting, Sponsor: Neuren Pharmaceuticals Limited
- TAK-901 / Takeda
Enrollment change, Metastases: A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies (clinicaltrials.gov) - Jun 30, 2013
P1, N=31, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting --> Completed N=65 --> 31
- | TAK-901 / Takeda
Trial completion, Metastases: A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies (clinicaltrials.gov) - Jun 30, 2013
P1, N=31, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
N=65 --> 31 Active, not recruiting --> Completed
- || Enrollment change: Non-invasive Prenatal Diagnostic Validation Study (clinicaltrials.gov) - Jun 27, 2013
P=N/A, N=1781, Completed, Sponsor: Natera, Inc.
Active, not recruiting --> Completed N=4640 --> 1781
- ||| Trial completion: Non-invasive Prenatal Diagnostic Validation Study (clinicaltrials.gov) - Jun 27, 2013
P=N/A, N=1781, Completed, Sponsor: Natera, Inc.
N=4640 --> 1781 Recruiting --> Completed
- ||||| thioguanine / Generic mfg.
Enrollment change: Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 25, 2013
P3, N=254, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed N=158 --> 254
- Trial completion: Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies (clinicaltrials.gov) - Jun 19, 2013
P1/2, N=5, Completed, Sponsor: University Hospital, Toulouse
N=158 --> 254 Active, not recruiting --> Completed
- Enrollment change: Assessment of Bone Density and Bone Turnover Markers in Patients With Down Syndrome and Comparison to the Ts65Dn Model (clinicaltrials.gov) - Jun 18, 2013
P=N/A, N=60, Active, not recruiting, Sponsor: University of Arkansas
Active, not recruiting --> Completed N=30 --> 60
- Enrollment change: Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome (clinicaltrials.gov) - Jun 12, 2013
P4, N=43, Completed, Sponsor: Line Cleemann
N=30 --> 60 N=60 --> 43
- Trial completion: Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome (clinicaltrials.gov) - Jun 12, 2013
P4, N=43, Completed, Sponsor: Line Cleemann
N=60 --> 43 Active, not recruiting --> Completed
- Norditropin (somatropin) / Novo Nordisk
Trial termination: Initiating Transdermal Estradiol Therapy in Turner's Syndrome (clinicaltrials.gov) - Jun 5, 2013
P1, N=1, Terminated, Sponsor: University of Chicago
Active, not recruiting --> Completed Recruiting --> Terminated; Poor accrual
- Norditropin (somatropin) / Novo Nordisk
Enrollment change: Initiating Transdermal Estradiol Therapy in Turner's Syndrome (clinicaltrials.gov) - Jun 5, 2013
P1, N=1, Terminated, Sponsor: University of Chicago
Recruiting --> Terminated; Poor accrual N=60 --> 1
- Trial termination: The Natural History of Reproductive and Overall Health in Girls and Women With a Pre-Mutation in the FMR1 Gene; Creation of a Patient Registry (clinicaltrials.gov) - May 31, 2013
P=N/A, N=7, Terminated, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
N=60 --> 1 Recruiting --> Terminated
- Enrollment change: The Natural History of Reproductive and Overall Health in Girls and Women With a Pre-Mutation in the FMR1 Gene; Creation of a Patient Registry (clinicaltrials.gov) - May 31, 2013
P=N/A, N=7, Terminated, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting --> Terminated N=1000 --> 7
- Trial termination: Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler (clinicaltrials.gov) - May 26, 2013
P=N/A, N=264, Terminated, Sponsor: Skyline Diagnostics BV
Recruiting --> Terminated; The required number of banked samples could not be met due to limited availability. There is no realistic possibility to complete the study succesfully.
- Enrollment change: Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler (clinicaltrials.gov) - May 26, 2013
P=N/A, N=264, Terminated, Sponsor: Skyline Diagnostics BV
There is no realistic possibility to complete the study succesfully. N=545 --> 264
- || Trial initiation date: EXPLAIN -FragilE X Registry: An exPlorative Longitudinal Study for chAracterIzation, Treatment Pathways and patieNt-related Outcomes (clinicaltrials.gov) - May 9, 2013
P=N/A, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
N=545 --> 264 Initiation date: Oct 2012 --> Apr 2013
- ||| Enrollment open: EXPLAIN -FragilE X Registry: An exPlorative Longitudinal Study for chAracterIzation, Treatment Pathways and patieNt-related Outcomes (clinicaltrials.gov) - May 9, 2013
P=N/A, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Oct 2012 --> Apr 2013 Not yet recruiting --> Recruiting
- Nebido (testosterone undecanoate depot injection) / Bayer
Enrollment open: ALCeP: Androgen for Leydig Cell Proliferation (clinicaltrials.gov) - May 4, 2013
P2/3, N=20, Recruiting, Sponsor: University of Roma La Sapienza
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- topiramate / Generic mfg.
Trial completion: Treatment of Self-Injurious Behavior in Individuals With Prader-Willi Syndrome (clinicaltrials.gov) - Apr 29, 2013
P=N/A, N=10, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting --> Recruiting Recruiting --> Completed
- Enrollment change: Turner Syndrome: Genotype and Phenotype (clinicaltrials.gov) - Apr 24, 2013
P=N/A, N=1017, Active, not recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting --> Completed N=1300 --> 1017
- Enrollment closed: Turner Syndrome: Genotype and Phenotype (clinicaltrials.gov) - Apr 24, 2013
P=N/A, N=1017, Active, not recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
N=1300 --> 1017 Recruiting --> Active, not recruiting
- azacitidine / Generic mfg.
Trial completion: Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities (clinicaltrials.gov) - Apr 22, 2013
P2, N=40, Completed, Sponsor: King's College London
Recruiting --> Active, not recruiting Recruiting --> Completed
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment change, Epigenetic controller: Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia (clinicaltrials.gov) - Apr 15, 2013
P1, N=34, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=46 --> 34
- sertraline / Generic mfg.
Enrollment change: Trial of Sertraline to Treat Children With Fragile X Syndrome (clinicaltrials.gov) - Apr 4, 2013
P=N/A, N=72, Recruiting, Sponsor: University of California, Davis
N=46 --> 34 N=60 --> 72